← 홈

Antibody · 고형암 (전체)

399개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 399개
AntibodyThe First Affiliated Hospital o…Phase 2

Adebellizumab (Adebellizumab)

Resectable Lung Non-Small Cell Carcinoma · Resectable Lung Non-Small Cell Carcinoma

#ResectableLungNon-SmallCellCarci#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleGilead SciencesPhase 1

Andecaliximab (Andecaliximab)

Gastric Adenocarcinoma · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase1#항체#면역항체+3
효능 ORR 9.7%임상시험 3상태 DISCONTINUED
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization)

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Inter… · Advanced Hepatocellular Carcinoma (HCC),

#AdvancedHepatocellularCarcinomaH#Antibody#Preclinical#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleRochePhase 2

bevacizumab (Avastin, Avastin (bevacizumab))

Recurrent Respiratory Papillomatosis · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 3상태 ACTIVE
AntibodystaleAVEO Pharmaceuticals, Inc.Phase 2

Ficlatuzumab (Ficlatuzumab)

Head and Neck Basaloid Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma · Carcinoma, Squamous Cell of Head and Nec

#CarcinomaSquamousCellofHeadandNe#Antibody#Phase2#항체#면역항체+4
효능 ORR 1%임상시험 3상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

Niraparib + Ipilimumab (Niraparib + Ipilimumab)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 7.7%임상시험 3상태 ACTIVE
AntibodyRochePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+carboplatin±bevacizumab)

Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleGenentech, Inc.Phase 1

XmAb24306 (XmAb24306)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 3상태 ACTIVE
AntibodystaleRochePreclinical

atezolizumab (Tecentriq, atezolizumab plus bevacizumab)

Hepatocellular Carcinoma; Hepatic Portal Vein Tumor Invasion · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#Antibody#Preclinical#항체#면역항체+4
효능 ORR 49.3%임상시험 3상태 ACTIVE
AntibodyDwight OwenPhase 1

Adenosine A2B Receptor Antagonist PBF-1129 (Adenosine A2B Receptor Antagonist PBF-1129)

Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Lung Non-Small Cell Carcinoma

#MetastaticLungNon-SmallCellCarci#Antibody#Phase1#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleJiangsu HengruiPhase 2

Albumin-paclitaxel + carboplatin + apatinib + camrelizumab (Albumin-paclitaxel + carboplatin + apatinib + camrelizumab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleRocheApproved

atezolizumab (Tecentriq, Atezolizumab Injection [Tecentriq])

Hepatocellular Carcinoma · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Approved#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, Etoposide, Carboplatin, Tarlatamab)

Small Cell Carcinoma of Lung · Small Cell Carcinoma of Lung

#SmallCellCarcinomaofLung#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodystaleAmgenPhase 2

Bemarituzumab (Bemarituzumab)

Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.8%임상시험 2상태 ACTIVE
AntibodystaleEli LillyPhase 2

CDX-3379 and cetuximab (CDX-3379 and cetuximab)

Advanced Head and Neck Squamous Cell Carcinoma · Advanced Head and Neck Squamous Cell Car

#AdvancedHeadandNeckSquamousCellC#Antibody#Phase2#항체#면역항체+2
효능 ORR 7%임상시험 2상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Coformulated vibostolimab/pembrolizumab)

Metastatic Urothelial Carcinoma; Urothelial Neoplasms · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodystaleMacroGenicsPhase 3

Enoblituzumab (Enoblituzumab)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 6%임상시험 2상태 DISCONTINUED
AntibodystaleQilu Pharmaceutical Co., Ltd.Phase 2

QL1706 (Iparomlimab and Tuvonralimab Injection, Iparomlimab and Tuvonralimab Injection (QL1706))

Hepatocellular Carcinoma (HCC); Immunotherapy · Hepatecellular Carcinoma

#HepatecellularCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleMerck KGaAPhase 1

Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 ACTIVE

5 / 20 페이지

← 이전다음 →